Please assess the completion status of the following clinical trial:

Trial Title: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the patient is below the age of consent (according to local regulations), the parent/caregiver should be able and willing to give consent, and the patient be informed about the study and asked to give positive assent, if feasible~2. Age: Is aged 18 years or older (Stage 1) or 15 years or older (Stage 2)~3. AFB or GeneXpert results: Has a positive AFB sputum smear result at screening (at least scanty), or a positive GeneXpert result (with a cycle threshold (Ct) value of 25 or lower) from a test performed at screening or from a test performed within the four weeks prior to screening~4. Has evidence of resistance to rifampicin either by line probe assay (Hain Genotype), GeneXpert or culture-based drug susceptibility testing (DST), from a test performed at screening or from a test performed within the four weeks prior to screening~5. Is willing to have an HIV test and, if positive, is willing to be treated with ART in accordance with the national policies but excluding ART contraindicated for use with bedaquiline~6. Is willing to use effective contraception: pre-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilised must agree to use a barrier method or an intrauterine device unless their partner has had a vasectomy; men who have not had a vasectomy must agree to use condoms. In Stage 2 pre-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilised must agree to use two methods of contraception, for example a hormonal method and a barrier method~7. Resides in the area and expected to remain for the duration of the study.~8. Has had a chest X-ray that is compatible with a diagnosis of pulmonary TB (if such a chest X-ray taken within 4 weeks of randomisation is available, a repeat X-ray is not required)~9. Has normal K+, Mg2+ and corrected Ca2+ at screening.~Exclusion Criteria:~1. Is infected with a strain of M. tuberculosis resistant to second-line injectables by line probe assay (Hain Genotype) from a test performed at screening or from a test performed within the four weeks prior to screening~2. Is infected with a strain of M. tuberculosis resistant to fluoroquinolones by line probe assay (Hain Genotype) from a test performed at screening or from a test performed within the four weeks prior to screening~3. Has tuberculous meningitis or bone and joint tuberculosis~4. Is critically ill, and in the judgment of the investigator, unlikely to survive more than 4 months~5. Is known to be pregnant or breast-feeding~6. Is unable or unwilling to comply with the treatment, assessment, or follow-up schedule~7. Is unable to take oral medication~8. Has AST or ALT more than 5 times the upper limit of normal for Stage 1, and AST or ALT more than 3 times the upper limit of normal for Stage 2~9. Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe~10. In the investigator's opinion the patient is likely to be eligible for treatment with bedaquiline according to local guidelines due to a pre-existing medical condition such as hearing loss or renal impairment~11. Is taking any medications contraindicated with the medicines in any trial regimen~12. Has a known allergy to any fluoroquinolone antibiotic~13. Is currently taking part in another trial of a medicinal product~14. Has a QT or QTcF interval at screening or immediately prior to randomisation of more than or equal to 500 ms for Stage 1, and more than or equal to 450 ms for Stage 2~    In addition to the criteria above, for Stage 2 only, a patient will not be eligible for randomisation to the study if he/she:~15. Has experienced one or more of the following risk factors for QT prolongation:~    * A confirmed prolongation of the QT or QTcF more than or equal to 450 ms in the screening ECG (retesting to reassess eligibility will be allowed once using an unscheduled visit during the screening phase)~   * Pathological Q-waves (defined as Q-wave more than 40 ms or depth more than 0.4-0.5 mV)~   * Evidence of ventricular pre-excitation (e.g., Wolff Parkinson White syndrome)~   * Electrocardiographic evidence of complete or clinically significant incomplete left bundle branch block or right bundle branch block~   * Evidence of second or third degree heart block~   * Intraventricular conduction delay with QRS duration more than 120 ms~   * Bradycardia as defined by sinus rate less than 50 bpm~   * Personal or family history of Long QT Syndrome~   * Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, with the exception of sinus arrhythmia~   * Syncope (i.e. cardiac syncope not including syncope due to vasovagal or epileptic causes)~   * Risk factors for Torsades de Pointes (e.g., heart failure, hypokalaemia, or hypomagnesemia)~16. Has received treatment for MDR-TB in the 12 weeks prior to screening, other than the maximum permitted treatment specified in Section 5.2.1~17. Has a history of cirrhosis and classified as Child's B or C at screening or a bilirubin more than 1.5 times upper limit of normal.~18. Has an estimated creatinine clearance (CrCl) less than 30 mL/min based on the Cockcroft-Gault equation~19. Is HIV positive and has a CD4 count less than 50 cells/mm3~20. Has pancreatic amylase elevation more than two times above the upper limit of normal~21. Has a history of alcohol and/or drug abuse~22. Has had previous treatment with bedaquiline~23. Has taken rifampicin in the seven days prior to randomisation~24. There has been a delay of more than four weeks between the screening consent and randomisation~25. Is an employee or family member of the investigator or study site staff with direct involvement in the proposed study.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen A (Type: ACTIVE_COMPARATOR): Regimen A locally-used WHO-approved MDR-TB regimen in accordance with 2011 WHO MDR-TB treatment guidelines.
- Regimen B (Type: ACTIVE_COMPARATOR): Regimen B is based on the regimen described by Van Deun 2010. With Version 8.0 of the protocol Regimen B (Regimen Bmox) is modified by replacement of moxifloxacin with levofloxacin (Regimen Blev). Regimen B without specification of which fluoroquinolone is in the regimen refers to either (Bmox or Blev).~Product and dose for \[\<33 kg, 33-50kg, \>50 kg\] respectively:~Moxifloxacin \[400mg, 600mg, 800mg\] OR Levofloxacin \[750mg, 750mg,1000mg\]; Clofazimine \[50mg,100mg,100mg\]; Ethambutol \[800mg,800mg,1200mg\]; Pyrazinamide \[1000mg,1500mg, 2000mg\]; Isoniazid 300mg, 400mg, 600mg\]; Prothionamide \[250mg,500mg,750mg\]; Kanamycin \[15mg per kilogram body weight (maximum 1g)\].
- Regimen C (Type: EXPERIMENTAL): Regimen C is a 40-week all-oral regimen consisting of bedaquiline, clofazimine, ethambutol, levofloxacin, and pyrazinamide given for 40 weeks supplemented by isoniazid and prothionamide for the first 16 weeks (intensive phase).~Product and dose for \[\<33kg, 33-50kg, \>50 kg\] respectively:~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin \[750mg, 750mg,1000mg\]; Clofazimine \[50mg, 100mg, 100mg\]; Ethambutol \[800mg, 800mg, 1200mg\]; Pyrazinamide \[1000mg,1500mg, 2000mg\]; Isoniazid \[300mg, 400mg, 600mg\]; Prothionamide \[250mg, 500mg,750mg\].
- Regimen D (Type: EXPERIMENTAL): Regimen D is a 28-week regimen consisting of bedaquiline, clofazimine, levofloxacin, and pyrazinamide given for 28 weeks supplemented by isoniazid and kanamycin for the first 8 weeks (intensive phase).~Product and dose for \[\<33kg, 33 to\<40kg, 40-50kg, \>50-60 kg, \>60 kg\] respectively:~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin \[750mg, 750mg, 750mg, 1000mg, 1000mg\]; Clofazimine \[50mg, 100mg, 100mg, 100mg, 100mg\]; Pyrazinamide \[1000mg,1500mg, 1500mg, 2000mg, 2000mg\]; Isoniazid \[400mg, 500mg, 600mg, 800mg, 900mg\]; Kanamycin \[15 mg per kilogram body weight (maximum 1g)\].

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete